

2019. 4. 23



Save the Dates!

April 25 - 28, 2020



Website



Webcast

24th CARDIOVASCULAR SUMMIT
TCTAP2019



2F Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea

Tel 82-2-3010-4940 | Fax 82-2-475-6898 | E-mail namoon@summitmd.com

FINAL PROGRAM

24th CARDIOVASCULAR SUMMIT **TCTAP2019**

Coronary Intervention
Percutaneous Valve Therapeutics
Endovascular Intervention
CTO Intervention



April 27-30, 2019
COEX, Seoul, Korea

www.summit-tctap.com

TCTAP 2019 in Your Hands

Download the TCTAP App!




TABLE OF CONTENTS

MEETING INFORMATION

BOARD MEMBERS	6
COLLABORATIONS	8
ACKNOWLEDGEMENTS	10
MEETING AT A GLANCE	12
SPECIAL ACTIVITIES	16
GENERAL INFORMATION	17

SATELLITE SYMPOSIUM	23
---------------------	----

TRAINING CENTER	29
-----------------	----

PARTNERSHIP SESSIONS	33
----------------------	----


EXHIBITION GUIDE	35
------------------	----

Watch Live[📶]

TCTAP 2019 Webcast
Anytime, Anywhere



Webcast.summitmd.com



24th CARDIOVASCULAR SUMMIT
TCTAP2019

TCTAP

MEETING INFORMATION

BOARD MEMBERS	6
COLLABORATIONS	8
ACKNOWLEDGEMENTS	10
MEETING AT A GLANCE	12
SPECIAL ACTIVITIES	16
GENERAL INFORMATION	17

BOARD MEMBERS



Course Directors

Seung-Jung Park, MD	Martin Bert Leon, MD
Duk-Woo Park, MD	Gregg W. Stone, MD

Course Co-Directors

Myeong-Ki Hong, MD	John Robert Laird, Jr., MD
Donghoon Choi, MD	Alan C. Yeung, MD
Bon-Kwon Koo, MD	William F. Fearon, MD
Seung-Whan Lee, MD	Ajay J. Kirtane, MD
Jung-Min Ahn, MD	Susheel Kodali, MD

Scientific Committee

Youngkeun Ahn, MD	Byeong-Keuk Kim, MD
Takashi Akasaka, MD	Ho Jung Kim, MD
Rosli Mohd Ali, MD	Hojin Kim, MD
Yasushi Asakura, MD	June Hong Kim, MD
Jang-Ho Bae, MD	Jung-Sun Kim, MD
Seung Hyuk Choi, MD	Jae-Hwan Lee, MD
Suk Jung Choo, MD	Michael Kang-Yin Lee, MD
George D. Dangas, MD	Chang-Wook Nam, MD
Doni Firman, MD	Satoru Otsuji, MD
William A. Gray, MD	Afzalur Rahman, MD
Joo-Yong Hahn, MD	Li Wah Tam, MD
Young Joon Hong, MD	Etsuo Tsuchikane, MD
Xinyang Hu, MD	Wasan Udayachalerm, MD
Seung-Ho Hur, MD	Jian-an Wang, MD
Jae-Sik Jang, MD	Chiung-Jen Wu, MD
Woong Chol Kang, MD	Bo Xu, MD
Paul Hsien-Li Kao, MD	Robaayah Zambahari, MD
Dimitrios Karpaliotis, MD	

Honorary Board

Antonio Colombo, MD	Spencer B. King III, MD
Runlin Gao, MD	Gary S. Mintz, MD
Junbo Ge, MD	Toshiya Muramatsu, MD
Eberhard Grube, MD	Masakiyo Nobuyoshi, MD
David R. Holmes, MD	Nico Pijls, MD
Yong Huo, MD	Barry D. Rutherford, MD
Ik-Kyung Jang, MD	Teguh Santoso, MD
Yangsoo Jang, MD	Patrick W. Serruys, MD
Hyo-Soo Kim, MD	Ki-Bae Seung, MD
Jae-Joong Kim, MD	Junghan Yoon, MD

COLLABORATIONS



Live Centers & Operators

TCTAP 2019 will be streamed live from world-renowned international medical centers. Discover the distinguished line-up of live Centers and operators.

Korea Live Transmission Site

Asan Medical Center, Seoul, Korea

Jung-Min Ahn, MD | Vinayak Bapat, MD | Robert Bersin, MD | Sang-Cheol Cho, MD
Antonio Colombo, MD | James Flaherty, MD | Eberhard Grube, MD | Osamu Iida, MD
Do-Yoon Kang, MD | Se Hun Kang, MD | Paul Hsien-Li Kao, MD | Hojin Kim, MD | Su Hong Kim, MD
Euihong Ko, MD | Young-Guk Ko, MD | Osung Kwon, MD | Chang Hoon Lee, MD | Cheol Hyun Lee, MD
Jae-Hwan Lee, MD | Jong-Young Lee, MD | Kyusup Lee, MD | Michael S. Lee, MD | Pil Hyung Lee, MD
Seung-Whan Lee, MD | Thierry Lefevre, MD | Duk-Woo Park, MD | Gyung-Min Park, MD
Hanbit Park, MD | Hyun Woo Park, MD | Seung-Jung Park, MD | Horst Sievert, MD | Jon Suh, MD
Etsuo Tsuchikane, MD | Gerald Werner, MD | Alan C. Yeung, MD | Yong-Hoon Yoon, MD

Severance Hospital, Seoul, Korea

Chul-Min Ahn, MD | Myeong-Ki Hong, MD | Sung-Jin Hong, MD | Byeong-Keuk Kim, MD
Young-Guk Ko, MD | Jung-Hee Lee, MD | Kambis Mashayekhi, MD | Toshiya Muramatsu, MD
Kenya Nasu, MD | Hoyoun Won, MD

International Live Transmission Site

Columbia University Medical Center, New York, USA

Dimitrios Karpaliotis, MD | Ajay J. Kirtane, MD

St. Paul's Hospital, Vancouver, Canada

Anson Cheung, MD | John Graydon Webb, MD

Factoid & Live Case Review

Abdulazizi Almokhef, MD | Yeong Jin Jeong, MD | Ju Hyeon Kim, M | Jung Hoon Lee, MD

Daily Newspaper Committee

Duk-Woo Park, MD | Jung-Min Ahn, MD | Se-Whan Lee, MD | Se Hun Kang, MD | Do-Yoon Kang, MD
Pil Hyung Lee, MD | Jun-Hyok Oh, MD | Euihong Ko, MD | Chang Hoon Lee, MD | Chulhyun Lee, MD
Kyusup Lee, MD | Osung Kwon, MD | Yong-Hoon Yoon, MD | Sangwoo Park, MD | Hanbit Park, MD
Sang-Cheol Cho, MD | Hyun Woo Park, MD | Mineok Chang, MD

Associations and Affiliations

- Alliance for Revolution and Interventional Cardiology Advancement
- American College of Cardiology
- Annual Australia & New Zealand Endovascular Therapies Meeting
- Annual Live Demonstration in Kokura
- Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery
- Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics
- Annual Meeting of the Japanese Coronary Association
- Annual Scientific Congress
- Annual Scientific Meeting of Indonesian Heart Association
- Annual Scientific Meeting of NHAM
- Annual Scientific Meeting of the Japanese Circulation Society
- Annual Scientific Session of Japanese College of Cardiology
- Asia Pacific Congenital & Structural Heart Intervention Symposium
- Asia Pacific Society of Cardiology Congress
- Asia Pacific Society of Interventional Cardiology
- Asia Pacific Vascular Interventional Course
- Asian Interventional Cardiovascular Therapeutics
- Bangla Interventional Therapeutic
- Cardiological Society of India
- CardioRhythm
- Cardiovascular Interventional Association of Thailand
- Cardiovascular Interventional Summit HongKong
- Cardiovascular Research Technologies
- China Interventional Therapeutics in Partnership with TCT
- Chronic Total Occlusion Summit
- Chugoku Shikoku Live Demonstration Course in Kurashiki
- Complex Cardiovascular Therapeutics
- Congenital & Structural Interventions & Imaging in Cardiovascular Interventions
- Fuctional Revascularization Encouraged by optimal Diagnostic Strategy Live
- Great Wall International Congress of Cardiology
- Heart Institute of Asan Medical Center
- Hong Kong Society of Transcatheter Endocardiovascular Therapeutics
- IndiaLive
- Indonesian Society of Interventional Cardiology Annual Meeting
- Japan Endovascular Treatment Conference
- Japanese Association of Cardiovascular Intervention and Therapeutics
- Joint Interventional Meeting
- Joint meeting of Coronary Revascularization
- Kamakura Live Demonstration Course
- Kinki Cardiovascular Joint Live
- Korean Association of Cardiovascular and Pulmonary Rehabilitation
- Korean Cardiovascular Nurses Association
- Korean Cardiovascular Technology Association
- Korean Pediatric Heart Association
- Korean Society of Cardiology
- Korean Society of Cardiovascular Imaging
- Korean Society of Interventional Cardiology
- Left Main&Coronary Bifurcation Summit
- Malaysian LIVE Meeting
- Paris Course on Revascularization
- Qianjiang International Cardiovascular Congress
- Sapporo Live Demonstration Congress
- Taiwan Transcatheter Therapeutics Live Course
- TCT Russia
- The Heart & Brain Symposium
- Tokyo Percutaneous cardiovascular Intervention Conference
- Toyohashi Live Demonstration Course
- Transcatheter Cardiovascular Therapeutics
- Transcatheter Endocardiovascular Intervention Conference
- Transcatheter Valve Therapies
- Vascular Intervention Advances
- Vietnam National Congress of Cardiology

ACKNOWLEDGEMENTS



CardioVascular Research Foundation

Kyung-Ae Kim

Executive Director

Convention Div.

Moon Na

Director / Exhibition, Industry Relations

Emilie Cho

Manager / Faculty Sponsorship & Travel Arrangement, Case Submission

Sohee Park

Manager / Marketing

Hee Won Kim

Manager / Faculty Invitation & Schedule Arrangement, Live Transmission

Erin Jeong

Assistant Manager / Abstract Submission, Daily Newspaper

Training Div.

Hyerim Yun

Director / ACT & Fellowship Program, Stellite Symposium

Administrative, Accounting & Fundraising Div.

Karen KH Kim

Director / Administrative & Accounting

Bella Kim

Manager / Accounting & Meeting Registration

Jieun Kang

Research Management

Web & Graphic Development Div.

Soon-Jung Rho

Director

Jiwon Kang

Manager

Secretarial Div.

Mi-kyung Jung

Director

Commercial Supporters

Diamond	Abbott	Boston Scientific
	Medtronic Korea plc.	
Platinum	Yuhan Corporation	
Gold	Cardinal Health Korea Ltd.	Edwards Lifesciences Korea Co., Ltd.
	Pfizer Pharmaceutical Korea Ltd.	Biosensors Korea Limited
	CJ HealthCare	MSD KOREA
Silver	TERUMO	AstraZeneca Korea
	Bayer Korea	Sanofi-Aventis

Xience
Sierra™
Slim, but Bigger

SETTING THE STANDARD FOR SAFETY
RAISING THE BAR IN DELIVERABILITY

MAXIMAL EXPANSION

2.25 - 3.25mm → 3.75mm

3.5 - 4.0mm → 5.5mm

LOWEST CROSSING PROFILE

0.0390"

Xience Sierra™
Everolimus Eluting Coronary Stent System



MEETING AT A GLANCE



27 Saturday	Coronary Theater Level 1	Presentation Theater 1 Level 1	Presentation Theater 2 Level 1	Other Session Room	Abstract Zone I, II Level 1	Case Zone I, II, III Level 1
07:00						
07:30						
08:00						
08:30						
09:00						
09:30						
10:00						
10:30						
11:00		TCTAP workshop				
11:30		• Imaging & Physiology	TTT@TCTAP			
12:00						
12:30						
13:00		Satellite Symposia - Lunchtime Activities				
13:30						
14:00	22nd KCTA Symposium	TCTAP workshop	HKSTENT@TCTAP			
14:30		Left main and Bifurcation PCI				
15:00						
15:30						
16:00		TCTAP workshop	ISICAM (Indonesia), Malaysia Live & CIAT(Thailand) @TCTAP		Moderated Abstract Competition	Moderated Complex Case Competition
16:30	CE Program For Technologists *Korean Session	Complex PCI: Make It Simple				
17:00						
17:30		TCTAP workshop				
18:00		Valves				
18:30						
19:00						
19:30						
20:00						

28 Sunday	Main Arena Level 1	Coronary Theater Level 1	Presentation Theater 1 Level 1	Presentation Theater 2 Level 1	Other Session Room	Abstract Zone I, II Level 1	Case Zone I, II, III Level 1
07:00							
07:30							
08:00							
08:30							
09:00	Live Case Session I						
09:30	Opening						
10:00	Live Case Session II						
10:30							
11:00							
11:30	Master Award						
12:00							
12:30							
13:00							
13:30							
14:00							
14:30							
15:00							
15:30	Heart Keeper *Korean Session	TCT @ TCTAP	Hot Topics Antithrombotics	CIT @ TCTAP			
16:00			Hot Topics DES, BRS and DCB	CCT @ TCTAP		Moderated Abstract Competition	Moderated Complex Case Competition
16:30		Live Case & Lecture Session I					
17:00			Hot Topics Renal Denervation & LAA Closure				
17:30							
18:00							
18:30					Satellite Symposium Evening Symposium		
19:00							
19:30							
20:00							

MEETING AT A GLANCE



29 Monday	Coronary Theater	Presentation Theater 1	Presentation Theater 2	Other Session Room	Room 202	Abstract Zone I, II	Case Zone I, II, III		
	Level 1	Level 1	Level 1		Level 2	Level 1	Level 1		
07:00	Satellite Symposia Morning Roundtable Forum								
07:30									
08:00									
08:30	Live Case Session II 	Spotlights of Major Clinical Studies	Hot Topics Complex PCI		CE Program for Nurses *Korean Session	Moderated Abstract Competition	Moderated Complex Case Competition		
09:00									
09:30	2019 New Data from AMC	Hot Topics Left Main, Bifurcation & MVD PCI							
10:00									
10:30	Featured Clinical Research from Abstracts								
11:00									
11:30	Live Case Session IV								
12:00									
12:30	Satellite Symposia - Lunchtime Activities								
13:00									
13:30									
14:00	Live Case Session V 	Hot Topics Valves	Hot Topics CTO		Moderated Abstract Competition	Moderated Complex Case Competition			
14:30									
15:00	Live Case Session VI 	Hot Topics Imaging & Physiology	Hot Topics Endovascular						
15:30									
16:00	Live Case Session VII 								
16:30									
17:00									
17:30									
18:00	Satellite Symposium Evening Symposium								
18:30									
19:00									
19:30									
20:00									

30 Tuesday	Coronary Theater	Structural Heart & Endovascular Theater	Presentation Theater 1	Presentation Theater 2
	Level 1	Level 1	Level 1	Level 1
07:00	Satellite Symposia Morning Roundtable Forum			
07:30				
08:00				
08:30	Master the CTO 2019 Opening Remark & Live Case & Lecture Session I 	Structural Heart Disease Symposium Opening Remark & Live Case & Lecture Session I 	Challenging Case Competition with Experts' Focus Review	
09:00		Structural Heart Disease Symposium Live Case Session II		
09:30	Master the CTO 2019 Live Case Session II	Structural Heart Disease Symposium Live Case Session III		
10:00				
10:30	APCTO Club in TCTAP		Satellite Symposia - Lunchtime Activities	
11:00				
11:30	Master the CTO 2019 Live Case & Lecture Session III 	Endovascular Symposium Opening Remark & Live Case Session I 		
12:00		Endovascular Symposium Featured Session I		
12:30	Master the CTO 2019 Live Case & Lecture Session IV 	Endovascular Symposium Live Case Session II 		
13:00		Endovascular Symposium Featured Session II		
13:30				
14:00				
14:30				
15:00				
15:30				
16:00				
16:30				
17:00				
17:30				
18:00				
18:30				
19:00				
19:30				
20:00				

SPECIAL ACTIVITIES



TCTAP Wrap-up Interviews

Interview Studio, Level 2

	Time	Topics	Moderators	Interviewees
Saturday, April 27	12:45 PM ~ 1:05 PM	Imaging	Myeong-Ki Hong, Akiko Maehara	Evelyn Regar Takashi Akasaka Ik-Kyung Jang
	1:15 PM ~ 1:35 PM	Physiology	William F. Fearon, Seung-Jung Park	Nils Johnson Bon-Kwon Koo Jung-Min Ahn
Sunday, April 28	3:20 PM ~ 3:40 PM	Antithrombotics	Dominick J. Angiolillo, David J. Cohen	Joo-Yong Hahn Davide Capodanno Raj Makkar
	5:00 PM ~ 5:20 PM	DES	Stephen G. Ellis, Patrick W. Serruys	Aloke V. Finn Yoshinobu Onuma Michael Haude
Monday, April 29	11:00 AM ~ 11:20 AM	Complex	Chiung-Jen Wu, Marie-Claude Morice	Aloke V. Finn Akiko Maehara Philip M. Urban
	12:30 PM ~ 1:00 PM	LM & Bifurcation	Seung-Jung Park, Gregg W. Stone	John Ormiston Antonio Colombo Thierry Lefevre
	4:30 PM ~ 4:50 PM	Valve	Alain G. Cribier, Eberhard Grube	Raj Makkar Vinayak Bapat Saibal Kar

THE 9th TCTAP AWARD MASTER OF THE MASTERS

11:30 AM, Sunday, April 28
Main Arena, Level 3

This honorary award will be presented in the Main Arena, Level 3 on the 2nd day of meeting to the remarkable master who contributes to the advancement of interventional cardiology as well as in the TCTAP meeting over the last years.

TCTAP AWARD BEST YOUNG SCIENTIST AWARD

11:45 AM, Monday, April 29, 2019
Presentation Theater 1, Level 1

The 7th Best Young Scientist Award will be presented to encourage the winner's academic clinical work experience, efforts and participation to TCTAP.

GENERAL INFORMATION

ACT Tour (2 Hours)

(Asan Medical Center Interventional Cardiology Training Program)

• On-site registration & Pick-up Place: ACT Banner next to CVRF Booth, Grand Ballroom Lobby, Level 1

Date	Departure Time
Monday April 29	10:00 AM 2:00 PM

App

Bring the entire TCTAP2019 to your fingertips!



Certificate of Attendance

Certificate of Attendance for TCTAP2019 will be distributed along with the badge.

Coffee and Tea

During the coffee breaks, coffee and tea will be served to the registered participants at session rooms of level 1 and exhibition (B2) hall, only wearing their badge.

CVRF (Organizing Secretariat)

• CVRF Booth, Grand Ballroom Lobby, Level 1

Date	Opening Hours
Saturday, April 27	8:30 AM ~ 6:30 PM
Sunday, April 28 ~ Tuesday, April 30	6:00 AM ~ 6:00 PM

Cyber Station / Free Mobile Recharge

• CVRF Booth, Grand Ballroom Lobby, Level 1
• Lounge next to Registration Booth, Exhibition (B2) Hall Lobby, Level 1

Daily Newspaper

Each daily news edition will be distributed in the morning at the pick-up desk located right besides escalators, Level 1 and also available through TCTAP2019 Mobile App.

Join us and get a special gift!

Fill up the TCTAP Heart!
Leave a warm message to show your love and interest in TCTAP.
Your participation will make the heart "Perfect"

CVRF Booth, Grand Ballroom Lobby, Level 1

Saturday, April 27 ————— 8:30 AM ~ 6:30 PM
Sunday, April 28 ~ Tuesday, April 30 — 6:00 AM ~ 6:00 PM

GENERAL INFORMATION



Visit! 5 Exhibition Booths

Get! 5 Logos

Collect 5 Logos → Visit 5 Booths → Start!

Lucky Draw Box → Winner will draw a random gift

Win! Winner Announcement during the Exhibition Date Every 3:30 PM

★ Running Hours: 9:00 AM ~ 3:00 PM

★ Event paper will be provided at the registration booth and Lucky Draw Box will be located in front of Event Screen (Exhibition Hall, Level 1)

★ Winner announcement: Every 3:30 PM, during the Exhibition

Traditional Cultural Experience!

Korea Tourism Organization & tour Info Booth, Level 1, Grand Ballroom Lobby

Date/Opening Hours

April 27	08:30 AM ~ 6:00 PM
April 28 ~ April 30	09:00 AM ~ 6:00 PM

- Korean Calligraphy: Get your name written in Korean letters (Hangeul)
- Find out which tea best suits you and get your own tea cup.
- Experience the Beauty of Hanbok (Korean traditional outfit)

Exhibition

- Exhibition (B2) Hall, Level 1

Date	Opening Hours
Saturday, April 27	10:00 AM ~ 6:00 PM
Sunday, April 28 ~ Monday April 29	9:00 AM ~ 6:00 PM

Faculty Lounge

- Invited Faculty Lounge: Room 203, Level 2

Faculty of the Year Lounge: Exhibition (B2) Hall Lobby, Level 1

Date	Opening Hours
Saturday, April 27	8:30 AM ~ 6:30 PM
Sunday, April 28 ~ Tuesday, April 30	6:00 AM ~ 6:00 PM

※ Badges will be checked at the gate.

Future Meeting Desk

- Exhibition (B2) Hall Lobby, Level 1

Happy Hour

- Lounge, Exhibition (B2) Hall, Level 1

Snacks are provided during the running hours.

Date	Running Hours
Saturday, April 27	3:00 PM
Sunday, April 28	3:00 PM
Monday, April 29	10:00 AM, 3:00 PM

Information Desk

- CVRF Booth, Grand Ballroom Lobby, Level 1
- Registration Booth, Exhibition (B2) Hall Lobby, Level 1

If you have any problems or queries, please visit the information desk.

Learning Center

- Lounge, Exhibition (B2) Hall, Level 1
- Room 210, Level 2

Meal

All satellite symposia provide meals to attendees. Please ensure that you wear your badge at all times.

Parking Ticket

- Registration Booth, Exhibition (B2) Hall Lobby, Level 1

"Free Parking tickets are provided in a limited quantity on a first-come-first-served basis. After free parking tickets are exhausted, participants can purchase one-day parking permit at 50% discounted rate."

Prayer Room

- Level 3 (Nearby Conference Room E)

Date	Opening Hours
Saturday, April 27 ~ Tuesday April 30	03:00 AM ~ 10:00 AM

Preview Room

- Room 209, Level 2

All speakers should come at least 2 hours before presentation to upload and review their slides.

Date	Opening Hours
Saturday, April 27	8:30 AM ~ 6:30 PM
Sunday, April 28 ~ Tuesday, April 30	6:00 AM ~ 6:00 PM

Public Lounge

- CVRF Booth, Grand Ballroom Lobby, Level 1
- Lounge, Exhibition (B2) Hall, Level 1
- Lounge next to Registration Booth, Exhibition (B2) Hall Lobby, Level 1

Registration / Lost and Found / Coat Room

- Registration Booth, Exhibition (B2) Hall Lobby, Level 1

Date	Opening Hours
Saturday, April 27	8:30 AM ~ 6:30 PM
Sunday, April 28 ~ Tuesday, April 30	6:00 AM ~ 6:00 PM

Shuttle Bus

Free shuttle bus will be provided between COEX and several venue hotels. Visit the CVRF Booth for more information.

Sponsored By



Tour Information

- Grand Ballroom Lobby, Level 1

Tour information will be provided by COSMO JIN Tour and Seoul Metropolitan Government.

GENERAL INFORMATION

Visit Korea App – Brand new Visit Korea App has been released

Visit Korea provides extensive information on attractions, restaurants, accommodations, shopping, transportation, and the latest travel-related news to users.



1330 Korea Travel Hotline & Complaint Center



1330 Korea Travel Hotline, operated by Korea Tourism Organization (KTO), is a one-stop helpline available as a public service for local and international travelers. For any inquiries or complaints relating to Korean tourism, either beforehand or during your stay in Korea, you can seek assistance here as well.



Wi-Fi Zone

Structural Heart & Endovascular Theater


	EStructural Heart & Endovascular Theater
	Coronary Theater
	CTO Theater
	Presentation Theater 1
	Presentation Theater 2
	Grand Ballroom Lobby
	CVRF Booth
	Exhibition Lounge
	Registration Booth
	Faculty of the Year Lounge

Level 1

Level 2

Invited Faculty Lounge
Preview Room

NC EMERGE™ PTCA Dilatation Catheter



**THE FUTURE
BUILT ON A
LEGACY**



*The **Power Players***
in Dyslipidemia Treatment

Powerful
Lipid-Lowering Therapy

Monorova^{Tab.}

(Rosuvastatin Ca.)

5mg
10mg
20mg

A New Standard in Hyperlipidemia Treatment

Rosuvamibe Tablet

(Ezetimibe/Rosuvastatin Calcium)

10mg/5mg
10mg/10mg
10mg/20mg

A New Paradigm in Hyperlipidemia Treatment

※ 자세한 사항은 제품설명서를 참고하십시오. 홈페이지 : www.yuhan.co.kr / 소비자상담실 : 080-024-1188(수신자 요금부담)



24th CARDIOVASCULAR SUMMIT
TCTAP2019

Coronary Intervention

Percutaneous Valve Therapeutics

Endovascular Intervention

CTO Intervention

TCTAP

**SATELLITE
SYMPOSIUM**

SATELLITE SYMPOSIUM



Saturday, April 27

Lunchtime Activities

🕒 12:45 PM ~ 1:45 PM

Highlighting Lipitor's 20 Years of Evidence

Organized by CVRF and Supported by Educational Grant from Pfizer Pharmaceutical Korea Ltd.

📍 Presentation Theater 1, Level 1

"The Protection Dilemma for Patients with an Acute Coronary Event : How Do Current Anticoagulation and Antiplatelet Therapies Address It?"

Organized by CVRF and Supported by Educational Grant from ASPEN / HANDOK

📍 Presentation Theater 2, Level 1

Sunday, April 28

Morning Roundtable Forum: Meet the Experts over Breakfast

🕒 7:00 AM ~ 8:00 AM

Left Main & Bifurcation

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Coronary Theater, Level 1

Complex PCI: Debulking and Rotational Atherectomy

Organized by CVRF

📍 Presentation Theater 1, Level 1

Antithrombotics in High-Risk Patients

Organized by CVRF

📍 Presentation Theater 2, Level 1

Lunchtime Activities

🕒 12:45 PM ~ 1:45 PM

New Technical Solution to Complex CTO

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 Structural Heart & Endovascular Theater, Level 1

A Wholehearted Approach to Complex PCI

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Coronary Theater, Level 1

Evolut PRO Latest Innovation: A Workhorse Device to Treat All Patient

Organized by CVRF and Supported by Educational Grant from Medtronic Korea plc.

📍 Presentation Theater 1, Level 1

Protecting Patients with CVD in the Future

Organized by CVRF and Supported by Educational Grant from MSD KOREA

📍 Presentation Theater 2, Level 1

RIGHT STENT FOR RIGHT PATIENT

Organized by CVRF and Supported by Educational Grant from Biosensors Korea Limited

📍 Room 201, Level 2

How State-of-the-Art Technology Improves Patient-Oriented Outcomes

Organized by CVRF and Supported by Educational Grant from PHILIPS

📍 Room 202, Level 2

B. Braun Drug Coated Balloon Symposium

Organized by CVRF and Supported by Educational Grant from B. Braun Korea, Ltd., Co.

📍 Room 205, Level 2

Tailored Protection for Your Cardio-Vascular Patients: Insights from COMPASS Trial

Organized by CVRF and Supported by Educational Grant from Bayer Korea

📍 Room 1A, Level 3

Evening Symposium

🕒 6:00 PM ~ 8:15 PM

CHIP Symposium - KOREA and ASEAN Collaboration

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 Room 205, Level 2

Monday, April 29

Morning Roundtable Forum: Meet the Experts over Breakfast

🕒 7:00 AM ~ 8:10 AM

Coronary Imaging and Physiology

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Coronary Theater, Level 1

New DES and Stent Failure

Organized by CVRF

📍 Presentation Theater 1, Level 1

Valves

Organized by CVRF and Supported by Educational Grant from Edwards Lifesciences Korea Co., Ltd.

📍 Presentation Theater 2, Level 1

Lunchtime Activities

🕒 12:45 PM ~ 1:45 PM

The ERA of Drug Elution: New Technologies for SFA Treatment

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 Structural Heart & Endovascular Theater, Level 1

Delivering More Innovation of the Interventional Portfolio, Further Together

Organized by CVRF and Supported by Educational Grant from Medtronic Korea plc.

📍 Coronary Theater, Level 1

Complex PCI with Bifurcation Lesion (KBC/JBC/EBC)

Organized by CVRF and Supported by Educational Grant from Terumo

📍 Presentation Theater 1, Level 1

Asahi Intecc 4 Core Technologies

Organized by CVRF and Supported by Educational Grant from ASAHI INTECC CO.LTD

📍 Presentation Theater 2, Level 1

RIGHT STENT FOR RIGHT PATIENT

Organized by CVRF and Supported by Educational Grant from Biosensors Korea Limited

📍 Room 201, Level 2

Strategies to Optimize Management of Atherosclerotic CVD

Organized by CVRF and Supported by Educational Grant from Pfizer Pharmaceutical Korea Ltd.

📍 Room 205, Level 2

Evening Symposium

🕒 6:00 PM ~ 8:00 PM

APAC Endovascular Expert Meeting

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 Room 205, Level 2

Tuesday, April 30

Morning Roundtable Forum: Meet the Experts over Breakfast

🕒 7:00 AM ~ 8:10 AM

Aortic Intervention; Overcome the Complex Anatomy

Organized by CVRF and Supported by Educational Grant from Cook Medical Korea

📍 Structural Heart & Endovascular Theater, Level 1

Beyond the CTO: Treatment Strategies for Distal Bed

Organized by CVRF

📍 CTO Theater, Level 1

Lunchtime Activities

🕒 12:45 PM ~ 1:45 PM

Expand Patients Care in Endovascular Treatment

Organized by CVRF and Supported by Educational Grant from Medtronic Korea plc.

📍 Structural Heart & Endovascular Theater, Level 1

SAPIEN 3 TAVR

Organized by CVRF and Supported by Educational Grant from Edwards Lifesciences Korea Co., Ltd

📍 Presentation Theater 1, Level 1

Linear On-going Risk of CV Evnets in High-risk CAD Patients

Organized by CVRF and Supported by Educational Grant from AstraZeneca Korea

📍 Presentation Theater 2, Level 1

Stable·Strong·Safe¹⁻⁶

MachKhan[®] tab.

8/5mg, 16/5mg, 16/10mg

Candesartan cilexetil / Amlodipine besylate



180319 MACHKHA000-18-01

[Dosage Strengths] Machkhan tab, 8/5mg - Candesartan Cilexetil 8.00mg/Amlodipine Besylate 6.935mg (as Amlodipine 5mg), Machkhan tab, 16/5mg - Candesartan Cilexetil 16.00mg/Amlodipine Besylate 6.935mg (as Amlodipine 5mg), Machkhan tab, 16/10mg - Candesartan Cilexetil 16.00mg/Amlodipine Besylate 13.87mg (as Amlodipine 10mg) **[Indications]** Primary (Essential) hypertension NOT adequately controlled on Amlodipine or Candesartan monotherapy. **[Dosage and Administration]** The recommended dose is 1 tablet once daily to be taken with some water regardless of meal, preferably at the same time each day (e.g. in the morning). Individual dose titration with the components (i.e. amlodipine and candesartan) is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered. • 8/5mg : MACHKHA tab, 8/5mg may be administered in patients whose blood pressure is not adequately controlled with candesartan 8mg or amlodipine 5mg alone. • 16/5mg : MACHKHA tab, 16/5mg may be administered in patients whose blood pressure is not adequately controlled with candesartan 16mg or amlodipine 5mg alone. • 16/10mg : MACHKHA tab, 16/10mg may be administered in patients whose blood pressure is not adequately controlled with candesartan 16mg or amlodipine 10mg alone. For convenience, patients receiving candesartan and amlodipine from separate tablets may be switched to MACHKHA tab, containing the same component doses. **[Warnings]** Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, discontinue MACHKHA as soon as possible (see 7, Use in pregnancy and nursing mothers). * For further details, please refer to the insert paper

References 1. Van Liefdel et al, *Molecular and Cellular Endocrinology* 2009;302(2):237-243. 2. Lacourciere Y et al, *American Journal of Hypertension* 1999;12:1181-1187. 3. Hasegawa H et al, *Clin Exp Hypertens* 2012;34(2):86-91. 4. Elmfeldt D et al, *Blood Pressure* 2002;11:293-301. 5. Pfeffer MA et al, *Lancet* 2003; 362:759-766. 6. Yamaguchi J et al, *American Journal of Hypertension* 2010;106:819-824

24th CARDIOVASCULAR SUMMIT
TCTAP2019

TCTAP

**TRAINING
CENTER**

TRAINING CENTER



Saturday, April 27

Bifurcation Stenting Seminar Session 1

Organized by CVRF and Supported by Educational Grant from Terumo

📍 Training Center 3, Level 1
🕒 4:00 PM ~ 5:30 PM

Sunday, April 28

Advanced TAVR with Edwards

Organized by CVRF and Supported by Educational Grant from Edwards Lifesciences Korea Co., Ltd.

📍 Training Center 1, Level 1
🕒 2:00 PM ~ 3:30 PM

Renal Denervation & TAVR with Medtronic

Organized by CVRF and Supported by Educational Grant from Medtronic Korea plc.

📍 Training Center 2, Level 1
🕒 2:00 PM ~ 3:30 PM

Bifurcation Stenting Seminar Session 2

Organized by CVRF and Supported by Educational Grant from Terumo

📍 Training Center 3, Level 1
🕒 2:00 PM ~ 3:30 PM

Antegrade Dissection and Re-Entry (ADR) with Boston Scientific

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 CTO Training Center, Level 1
🕒 2:30 PM ~ 3:30 PM

Bifurcation Stenting Seminar Session 3

Organized by CVRF and Supported by Educational Grant from Terumo

📍 Training Center 3, Level 1
🕒 4:00 PM ~ 5:30 PM

Above the Call of Duty - PCI Optimization with OCT (Abbott)

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Training Center 2, Level 1
🕒 5:00 PM ~ 6:30 PM

Monday, April 29

Above the Call of Duty - PCI Optimization with OCT (Abbott)

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Training Center 2, Level 1
🕒 9:00 AM ~ 10:30 AM

Basic TAVR with Edwards

Organized by CVRF and Supported by Educational Grant from Edwards Lifesciences Korea Co., Ltd.

📍 Training Center 1, Level 1
🕒 10:00 AM ~ 11:30 AM

CTO Training Course: Lectures

Organized by Train Medical Trainers of Percutaneous Coronary Intervention (PCI) Institute

📍 CTO Training Center, Level 1
🕒 10:30 AM ~ 12:10 PM

Angiojet (Pharmaco-Mechanical Thrombectomy) with Boston Scientific

Organized by CVRF and Supported by Educational Grant from Boston Scientific

📍 Training Center 2, Level 1
🕒 11:00 AM ~ 12:00 PM

Renal Denervation & Primary Prevention with Medtronic

Organized by CVRF and Supported by Educational Grant from Medtronic Korea plc.

📍 Training Center 1, Level 1
🕒 2:00 PM ~ 3:00 PM

Peripheral Intervention with Abbott

Organized by CVRF and Supported by Educational Grant from Abbott

📍 Training Center 2, Level 1
🕒 2:00 PM ~ 3:30 PM

Bifurcation Stenting Seminar Session 4

Organized by CVRF and Supported by Educational Grant from Terumo

📍 Training Center 3, Level 1
🕒 2:00 PM ~ 3:30 PM

CTO Training Course: CTO Hands-on Training

Organized by Train Medical Trainers of Percutaneous Coronary Intervention (PCI) Institute

📍 CTO Training Center, Level 1
🕒 2:00 PM ~ 5:00 PM



For Healthcare Professional Only



Xarelto® Tailored Protection for Your Cardio-Vascular Patients¹



**STROKE
PREVENTION***



**VENOUS
PROTECTION***



*In non-valvular atrial fibrillation

*In pulmonary embolism, deep vein thrombosis, venous thromboembolism, total knee replacement, total hip replacement

References 1. Xarelto® (rivaroxaban), Prescribing Information, as approved by the Minister of Food and Drug Safety (the latest revision date: 05 Feb 2018).

[Product Name] Xarelto 2.5, 10, 15, 20mg **[Composition]** 1 tablet contains 2.5, 10, 15 and 20 mg of rivaroxaban **[Indications, Dosage and Administration]** 1. Risk reduction of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The recommended dose is 20 mg once daily. The recommended maximum daily dose is 20 mg. Patients with non-valvular atrial fibrillation who undergo PCI with stent placement should receive dose of 15 mg Xarelto once daily in addition to a P2Y12 inhibitor. This treatment regimen is recommended for a maximum of 12 months after PCI. 2. Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Risk reduction of recurrent DVT and PE. The recommended dose for the initial treatment of acute DVT is 15 mg Xarelto (at one time) twice daily for the first three weeks followed by 20 mg Xarelto once daily for the continued treatment and the prevention of recurrent DVT and PE. The recommended maximum daily dose is 20 mg during the first 3 weeks of treatment. In the following treatment phase the recommended maximum daily dose is 20 mg. 3. Prevention of venous thromboembolism (VTE) in adult patients undergoing major orthopedic surgery of the lower limbs (total knee or total hip replacement surgery). The recommended dose is one 10mg tablet (rivaroxaban 10mg) once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that haemostasis has been established. The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopedic surgery. But after hip replacement surgery patients are recommended to be treated for 5 weeks and after knee replacement surgery patients are recommended to be treated for 2 weeks. 4. Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus dipyridol, is indicated for reduction of atherothrombotic events rate (CV death and Myocardial Infarction) in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. The recommended dose is one 2.5 mg Xarelto tablet twice daily. Patients should also take a daily dose of 75-100 mg ASA or a daily dose 75-100 mg ASA in addition to a daily dose of 75 mg dipyridol. Treatment is recommended for at least 24 months. Patients after ACS continue to be at risk for cardiovascular events and therefore may benefit from extended treatment. For further information about Dosage and Administration, please see the full Xarelto® product information. **[Precautions for use]** 1. Warning 1) As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. 2) Xarelto administration should be discontinued if severe haemorrhage occurs. See 10. Overdose. Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery. 2. Contraindications 1) Patients with hypersensitivity to the active substance or to any of the excipients. 2) Patients with clinically significant active bleeding (e.g., intracranial bleeding, gastrointestinal bleeding). 3) Patients with hepatic disease which is associated with coagulopathy and patients with clinically relevant bleeding risk like Child Pugh B or C. 4) Pregnant and breast feeding women. 5) Xarelto contains lactose. Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 6) Patients with increased bleeding risk due to the below conditions: Recent gastrointestinal ulceration, recent intracranial haemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain, spinal or ophthalmic surgery, recent brain or spinal injury, known or suspected esophageal varices, arteriovenous malformations, Vascular aneurysms, presence of malignant neoplasms at high risk of bleeding. 7) Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, apixiban, dabigatran, etc.) except under the circumstances of switching therapy to or from rivaroxaban (see section 2.2) or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter. 8) Concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (TIA). 3. Adverse Reactions, Common (≥1/100 - <1/10): Anaemia (incl. respective laboratory parameters), Eye hemorrhage (incl. conjunctival hemorrhage), Gingival bleeding, Gastrointestinal tract hemorrhage (incl. rectal hemorrhage), Gastrointestinal and abdominal pains, Dyspepsia, Nausea, Constipation, Diarrhea, Vomiting, Fever, Edema peripheral, Decreased peripheral strength and energy (incl. fatigue and weakness), Post procedural hemorrhage (incl. postoperative anemia, and wound hemorrhage), Contusion, Eczema, Itching, Bruising, Pain in extremity, Bitterness, Headache, Urinary tract hemorrhage (incl. hematuria and menorrhagia), Renal impairment (incl. blood creatinine increased, blood urea increased), Epistaxis, Hemoptysis, Pruritus (incl. uncommon cases of generalized pruritus) Rash, Erythema, Cutaneous and subcutaneous hemorrhage, Hypotension, Hypotonia. **[Ethical Drug]** Imported and Manufactured by Bayer Korea Ltd. Korea. The latest revision date: 05-Feb-18.

For further detailed information, please refer to the full Xarelto® local product information or Bayer Korea website, <http://www.bayer.co.kr>

바이엘코리아㈜

(우 07071) 서울시 동작구 보라매로5길 23 삼성보라매메디티타워 7층 TEL 02-829-6600 | <http://www.bayer.co.kr> | COPYRIGHT©BAYER KOREA Limited | PP-XAR-KR-0396-1

24th CARDIOVASCULAR SUMMIT TCTAP2019

Coronary Intervention

Percutaneous Valve Therapeutics

Endovascular Intervention

CTO Intervention

TCTAP

PARTNERSHIP SESSIONS

PARTNERSHIP SESSIONS



Saturday, April 27

TTT @ TCTAP 2019

Co-organized by Taiwan Transcatheter Therapeutics

📍 Presentation Theater 2, Level 1

🕒 11:00 AM ~ 12:30 PM

HKSTENT @ TCTAP 2019: CHIP in Asia Pacific Region

Co-organized by HKSTENT

📍 Presentation Theater 2, Level 1

🕒 2:00 PM ~ 3:30 PM

3 Countries' Joint Session- ISICAM (Indonesia) & Malaysia LIVE & CIAT (Thailand) @ TCTAP 2019: "Interesting & Challenging Cases From South East Asia"

Co-organized by ISICAM (Indonesia) & Malaysia LIVE & CIAT (Thailand)

📍 Presentation Theater 2, Level 1

🕒 3:30 PM ~ 5:10 PM

Sunday, April 28

TCT @ TCTAP 2019

Co-Organized by TCT

📍 Coronary Theater, Level 1

🕒 2:00 PM ~ 4:00 PM

CIT @ TCTAP 2019

Co-organized by CIT

📍 Presentation Theater 2, Level 1

🕒 2:00 PM ~ 3:30 PM

CCT @ TCTAP 2019

Co-organized by CCT

📍 Presentation Theater 2, Level 1

🕒 3:30 PM ~ 5:00 PM

24th CARDIOVASCULAR SUMMIT TCTAP2019



EXHIBITION GUIDE

EXHIBITION HALL	36
EXHIBITORS	37
MAP	38

EXHIBITION HALL




L Learning Center
 C Coffee
 B Beverage
 G Gift
 S Simulator




EXHIBITORS

Company name	NO.	Company name	NO.
Abbott	B003	Guerbet Korea	B037
ACIST	B028	Jung Sung Medical Co., Ltd	B026
AICT-Asia PCR 2019	AB03	Korea Otsuka Pharmaceutical Co., Ltd.	B022
AMG KOREA Ltd./Qualitech Korea Ltd.	B011	Korean Society of Cardiology	AB01
ASAHI INTECC CO.LTD	B010	Korean Society of Interventional Cardiology	AB02
AstraZeneca Korea	B034	Medtronic Korea plc.	B002
B.Braun Korea, Ltd., Co.	B018	Meril Life Sciences Pvt. Ltd.	B024
Bayer Korea	B012	Merit Medical Korea	B030
Biosensors Korea Limited	B008	MicroPort Scientific Corporation	B025
BIOTRONIK	B016	MSD KOREA	B007
Boston Scientific	B004	NOVARTIS Korea	B013
Cardinal Health Korea Ltd.	B005	Pfizer Pharmaceutical Korea Ltd.	B020
CJ HealthCare	B006	PHILIPS	B017
Concept Medicals Research Pvt. Ltd.	B040	SAMJIN Pharm.	B039
Cook Medical Korea	B019	Sanofi-Aventis	B035
Daiichi Sankyo Korea	B015	Siemens Healthineers	B038
DONG-A ST	B032	Taiwan Transcatheter Therapeutics (TTT)	AB05
Edwards Lifesciences Korea Co., Ltd.	B001	Teleflex	B029
ELYSON PHARM	B027	Terumo Korea Corporation	B009
Endologix Korea Ltd.	B023	Yuhan Corporation	B033
Focusmedical Co., Ltd. / NIPRO / Infraredx	B014	Z-medica	B031
GE Healthcare	B021		


Level 3



Level 2



Level 1



- Information
- Men's Rest Room
- Women's Rest Room
- Wi-Fi
- Elevator
- Escalator

PHILIPS

Refinity

See clearly.
Treat optimally.

Refinity is the next generation of rotational IVUS catheter from Philips.

Providing **exceptional deliverability** in tortuous anatomies, **5F guide compatibility** suitable for radial access and **45 MHz high resolution image**, it's designed to meet the needs of your most complex PCI procedures.

innovation  you

www.philips.com/IGTdevices

© 2019 Koninklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. D000322585/A

STROKE

ACS

A-fib

PAD

LIVING PROOF

- ✓ Proven efficacy and a well-established safety profile across a broad range of atherothrombotic patients** with real-world experience in over 120 million*
- ✓ Studied in 10 major trials involving over 130,000 patients.

*1M5 (lower/lower) 0000 0000 0000 → 14 countries & channels available. Duration of treatment from internal data
→ ACS, recent MI, established PAD, recent ischemic stroke

STROKE

ACS

PAD

A-fib

Plavix
Clopidogrel 75mg
Take Protection Further. Today.

Plavix® tab 75mg

Contraindications: Each film-coated tablet contains 97.5mg of clopidogrel bisulfate (equivalent to 75mg of clopidogrel). **Indications:** 1. The reduction of atherothrombotic events in adult patients with ischemic stroke, myocardial infarction (MI) or established peripheral arterial disease (PAD). 2. The reduction of atherothrombotic events (cardiovascular death, MI, stroke or refractory ischemia) for adult patients with acute coronary syndrome (unstable angina or non-ST-segment MI), including patients who are to be managed medically, and those who are to be managed with percutaneous coronary intervention with or without stent or CABG. 3. Prevention of atherothrombotic and thromboembolic events including stroke in combination with aspirin in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin K antagonists (VKA) and who have a low bleeding risk. **Dosage and Administration:** Adults: 1. In patients with ischemic stroke, MI or established peripheral arterial disease, Plavix should be given as a single daily dose of 75mg. 2. In patients with acute coronary syndrome (unstable angina or non-ST-segment MI), Plavix should be given as a single daily dose of 75mg. 3. In patients with atrial fibrillation, Plavix should be given as a single daily dose of 75mg. 4. Plavix should be given in combination with aspirin. 5. Plavix should be given as a single daily dose of 75mg. 6. Plavix should be given in combination with aspirin. 7. Plavix should be given as a single daily dose of 75mg. 8. Plavix should be given in combination with aspirin. 9. Plavix should be given as a single daily dose of 75mg. 10. Plavix should be given in combination with aspirin. 11. Plavix should be given as a single daily dose of 75mg. 12. Plavix should be given in combination with aspirin. 13. Plavix should be given as a single daily dose of 75mg. 14. Plavix should be given in combination with aspirin. 15. Plavix should be given as a single daily dose of 75mg. 16. Plavix should be given in combination with aspirin. 17. Plavix should be given as a single daily dose of 75mg. 18. Plavix should be given in combination with aspirin. 19. Plavix should be given as a single daily dose of 75mg. 20. Plavix should be given in combination with aspirin. 21. Plavix should be given as a single daily dose of 75mg. 22. Plavix should be given in combination with aspirin. 23. Plavix should be given as a single daily dose of 75mg. 24. Plavix should be given in combination with aspirin. 25. Plavix should be given as a single daily dose of 75mg. 26. Plavix should be given in combination with aspirin. 27. Plavix should be given as a single daily dose of 75mg. 28. Plavix should be given in combination with aspirin. 29. Plavix should be given as a single daily dose of 75mg. 30. Plavix should be given in combination with aspirin. 31. Plavix should be given as a single daily dose of 75mg. 32. Plavix should be given in combination with aspirin. 33. Plavix should be given as a single daily dose of 75mg. 34. Plavix should be given in combination with aspirin. 35. Plavix should be given as a single daily dose of 75mg. 36. Plavix should be given in combination with aspirin. 37. Plavix should be given as a single daily dose of 75mg. 38. Plavix should be given in combination with aspirin. 39. Plavix should be given as a single daily dose of 75mg. 40. Plavix should be given in combination with aspirin. 41. Plavix should be given as a single daily dose of 75mg. 42. Plavix should be given in combination with aspirin. 43. Plavix should be given as a single daily dose of 75mg. 44. Plavix should be given in combination with aspirin. 45. Plavix should be given as a single daily dose of 75mg. 46. Plavix should be given in combination with aspirin. 47. Plavix should be given as a single daily dose of 75mg. 48. Plavix should be given in combination with aspirin. 49. Plavix should be given as a single daily dose of 75mg. 50. Plavix should be given in combination with aspirin. 51. Plavix should be given as a single daily dose of 75mg. 52. Plavix should be given in combination with aspirin. 53. Plavix should be given as a single daily dose of 75mg. 54. Plavix should be given in combination with aspirin. 55. Plavix should be given as a single daily dose of 75mg. 56. Plavix should be given in combination with aspirin. 57. Plavix should be given as a single daily dose of 75mg. 58. Plavix should be given in combination with aspirin. 59. Plavix should be given as a single daily dose of 75mg. 60. Plavix should be given in combination with aspirin. 61. Plavix should be given as a single daily dose of 75mg. 62. Plavix should be given in combination with aspirin. 63. Plavix should be given as a single daily dose of 75mg. 64. Plavix should be given in combination with aspirin. 65. Plavix should be given as a single daily dose of 75mg. 66. Plavix should be given in combination with aspirin. 67. Plavix should be given as a single daily dose of 75mg. 68. Plavix should be given in combination with aspirin. 69. Plavix should be given as a single daily dose of 75mg. 70. Plavix should be given in combination with aspirin. 71. Plavix should be given as a single daily dose of 75mg. 72. Plavix should be given in combination with aspirin. 73. Plavix should be given as a single daily dose of 75mg. 74. Plavix should be given in combination with aspirin. 75. Plavix should be given as a single daily dose of 75mg. 76. Plavix should be given in combination with aspirin. 77. Plavix should be given as a single daily dose of 75mg. 78. Plavix should be given in combination with aspirin. 79. Plavix should be given as a single daily dose of 75mg. 80. Plavix should be given in combination with aspirin. 81. Plavix should be given as a single daily dose of 75mg. 82. Plavix should be given in combination with aspirin. 83. Plavix should be given as a single daily dose of 75mg. 84. Plavix should be given in combination with aspirin. 85. Plavix should be given as a single daily dose of 75mg. 86. Plavix should be given in combination with aspirin. 87. Plavix should be given as a single daily dose of 75mg. 88. Plavix should be given in combination with aspirin. 89. Plavix should be given as a single daily dose of 75mg. 90. Plavix should be given in combination with aspirin. 91. Plavix should be given as a single daily dose of 75mg. 92. Plavix should be given in combination with aspirin. 93. Plavix should be given as a single daily dose of 75mg. 94. Plavix should be given in combination with aspirin. 95. Plavix should be given as a single daily dose of 75mg. 96. Plavix should be given in combination with aspirin. 97. Plavix should be given as a single daily dose of 75mg. 98. Plavix should be given in combination with aspirin. 99. Plavix should be given as a single daily dose of 75mg. 100. Plavix should be given in combination with aspirin. **Special Precautions:** 1. Patients who have lesions a propensity to bleed (ulcer etc.) and patient who are at risk of bleeding. 2. Hepatic impairment. 3. Renal impairment. 4. Acute ischemic stroke less than 7 days. 5. Concomitant use of drugs that inhibit CYP2C19. 6. Drug Interactions. 7. Bleeding patients. 8. Patients with low body weight. 9. Cross reactivity. 10. Acquired haemophilia. **Adverse Events:** 1. Hemorrhagic disorders. 2. Hemorrhagic disorders. 3. Hemorrhagic disorders. 4. Hemorrhagic disorders. 5. Hemorrhagic disorders. 6. Hemorrhagic disorders. 7. Hemorrhagic disorders. 8. Hemorrhagic disorders. 9. Hemorrhagic disorders. 10. Hemorrhagic disorders. 11. Hemorrhagic disorders. 12. Hemorrhagic disorders. 13. Hemorrhagic disorders. 14. Hemorrhagic disorders. 15. Hemorrhagic disorders. 16. Hemorrhagic disorders. 17. Hemorrhagic disorders. 18. Hemorrhagic disorders. 19. Hemorrhagic disorders. 20. Hemorrhagic disorders. 21. Hemorrhagic disorders. 22. Hemorrhagic disorders. 23. Hemorrhagic disorders. 24. Hemorrhagic disorders. 25. Hemorrhagic disorders. 26. Hemorrhagic disorders. 27. Hemorrhagic disorders. 28. Hemorrhagic disorders. 29. Hemorrhagic disorders. 30. Hemorrhagic disorders. 31. Hemorrhagic disorders. 32. Hemorrhagic disorders. 33. Hemorrhagic disorders. 34. Hemorrhagic disorders. 35. Hemorrhagic disorders. 36. Hemorrhagic disorders. 37. Hemorrhagic disorders. 38. Hemorrhagic disorders. 39. Hemorrhagic disorders. 40. Hemorrhagic disorders. 41. Hemorrhagic disorders. 42. Hemorrhagic disorders. 43. Hemorrhagic disorders. 44. Hemorrhagic disorders. 45. Hemorrhagic disorders. 46. Hemorrhagic disorders. 47. Hemorrhagic disorders. 48. Hemorrhagic disorders. 49. Hemorrhagic disorders. 50. Hemorrhagic disorders. 51. Hemorrhagic disorders. 52. Hemorrhagic disorders. 53. Hemorrhagic disorders. 54. Hemorrhagic disorders. 55. Hemorrhagic disorders. 56. Hemorrhagic disorders. 57. Hemorrhagic disorders. 58. Hemorrhagic disorders. 59. Hemorrhagic disorders. 60. Hemorrhagic disorders. 61. Hemorrhagic disorders. 62. Hemorrhagic disorders. 63. Hemorrhagic disorders. 64. Hemorrhagic disorders. 65. Hemorrhagic disorders. 66. Hemorrhagic disorders. 67. Hemorrhagic disorders. 68. Hemorrhagic disorders. 69. Hemorrhagic disorders. 70. Hemorrhagic disorders. 71. Hemorrhagic disorders. 72. Hemorrhagic disorders. 73. Hemorrhagic disorders. 74. Hemorrhagic disorders. 75. Hemorrhagic disorders. 76. Hemorrhagic disorders. 77. Hemorrhagic disorders. 78. Hemorrhagic disorders. 79. Hemorrhagic disorders. 80. Hemorrhagic disorders. 81. Hemorrhagic disorders. 82. Hemorrhagic disorders. 83. Hemorrhagic disorders. 84. Hemorrhagic disorders. 85. Hemorrhagic disorders. 86. Hemorrhagic disorders. 87. Hemorrhagic disorders. 88. Hemorrhagic disorders. 89. Hemorrhagic disorders. 90. Hemorrhagic disorders. 91. Hemorrhagic disorders. 92. Hemorrhagic disorders. 93. Hemorrhagic disorders. 94. Hemorrhagic disorders. 95. Hemorrhagic disorders. 96. Hemorrhagic disorders. 97. Hemorrhagic disorders. 98. Hemorrhagic disorders. 99. Hemorrhagic disorders. 100. Hemorrhagic disorders. **Other:** 1. Detailed information on this medicine: please refer to the leaflet or the website (www.sanofi.com)

SANOFI

Complex Cardiovascular Therapeutics 2019

CCT 2019

Dates **October 24th - 26th** sat., 2019

Venues **Kobe International Exhibition Hall
Portopia Hotel, Kobe, Japan**

- Coronary
- Peripheral
- Surgical
- Structural Heart Diseases
- Co-medical



CCT Website:
<https://cct.gr.jp/>

Facebook

<https://www.facebook.com/CCTJAPAN/>

Find us on
Facebook



Call for Abstracts & Cases deadline: June 13th Thu., 2019
Pre-registration period: June 1st Sat. - September 13th Fri., 2019

A background image for the CTO Club poster featuring a blue-toned world map with glowing white lines representing flight paths or connections between various cities.

The 20th Seminar of Angioplasty
of Chronic Total
Occlusions

CTO Club

[Dates]
June 14th Fri. - 15th Sat., 2019

[Venue]
WINC AICHI, Nagoya, Japan

Pre-registration deadline: May 20th Mon., 2019
<http://cct.gr.jp/ctoclub/>
Supported by Complex Cardiovascular Therapeutics



TOPIC 2019

**11 - 13, JULY
TOKYO**

TOKyo Percutaneous cardiovascular Intervention Conference



CIT2020

China Interventional Therapeutics in Partnership with TCT

Cooperation Innovation Transition

Save the Date

April 2-5, 2020

Thursday-Sunday



BEIJING, CHINA

China National Convention Center (CNCC)

For more information, please visit:

www.citmd.com

September
25-29, 2019

THE MOSCONE CENTER
SAN FRANCISCO, CA

TCTCONFERENCE.COM
#TCT2019

Join us in **San Francisco**
for the world's
preeminent educational
meeting specializing
in interventional
cardiovascular medicine.

tct2019



Cardiovascular
Research Foundation